Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "NFI"

1125 News Found

Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr
News | September 26, 2025

Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr

BIL also holds an option to increase its equity stake by an additional 15%


FUJIFILM India installs DR X-ray system at CHC Dholera
News | September 26, 2025

FUJIFILM India installs DR X-ray system at CHC Dholera

The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region


Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations
News | September 25, 2025

Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations

Ultra-high purity surfactant for biologics and parenteral drug formulations


Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad
News | September 24, 2025

Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad

Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices


Teva unveils promising SOLARIS resultsfor Olanzapine LAI
Clinical Trials | September 23, 2025

Teva unveils promising SOLARIS resultsfor Olanzapine LAI

No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks


Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration
News | September 19, 2025

Roche secures CE mark for Accu-Chek SmartGuide CGM with mySugr app integration

This predictive technology empowers people with diabetes to take preventive action before complications arise


Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025
Clinical Trials | September 19, 2025

Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025

The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States


AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials
Clinical Trials | September 19, 2025

AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials

Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing


AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
Clinical Trials | September 18, 2025

AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment

The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo